Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide during CPB for AKI prevention in neonates
NCT03946462Phase 1Withdrawn
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nitric oxide in acute kidney injury (AKI) (2 arms). Primary endpoints: Neutrophil Gelatinase-Associated Lipocalin level at 48 hours and Cystatin-C level at 48 hours. Planned start Oct 2021; status: withdrawn.
02
Drugs
nitric oxide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03946462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946462.